Correction to: Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms

Correction to: J Exp Clin Cancer Res

https://doi.org/10.1186/s13046-019-1295-8

In the publication of this article [1], there are two corrections: 1. The corresponding author Yuanzhong Chen’s email should be changed to chenyz@mail.fjmu.edu.cn; 2. Several figures Fig. 5, Fig. 8, and Additional files 5, 6, 9 and 10 need to be corrected, because the formats are wrong, and the revised figures are shown below.

Fig. 5

Homoharringtonine (HHT) combined with arsenic trioxide (ATO) decrease the proportion of primary leukemia stem cells (LSCs) in serum free medium with cytokine cocktail (Flt3L, SCF, IL-3 and IL-6). Quantification of frequencies of CD34⁺cells (a), CD34⁺/CD38⁻ cells (b) and CD34⁺/CD38⁻/CD96⁺ cells (c). (d) Display of flow cytometric analysis on bone marrow sample of patient no. 2 after treatment with HHT and ATO alone or combined. (e) Represents the proportion of normal primary CD34+/CD38- (n = 3)

Fig. 8

Homoharringtonine (HHT) combined with arsenic trioxide (ATO) remarkably obliterated the histological infiltration of leukemia stem cells (LSCs). (a) H&E-stained sections of representative 4% paraformaldehyde-fixed spleens and bone marrow from NRG mice. (b) hCD45 and hCD34 levels were detected in the different groups by confocal laser-scanning microscopy in representative 4% paraformaldehyde-fixed spleens and bone marrow samples from NRG mice. Scale bars: 50 μm

Table S1 Patients characteristic

Table S2 Primer Sequences for PCR

The original article has been corrected.